{"id":"amlodipine-atorvastatin","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Edema (peripheral)"},{"rate":"3–5%","effect":"Flushing"},{"rate":"2–5%","effect":"Muscle pain (myalgia)"},{"rate":"1–3%","effect":"Elevated liver enzymes"},{"rate":"2–4%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle and reduces peripheral vascular resistance, thereby lowering blood pressure. Atorvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and triglycerides while raising HDL cholesterol. Together, they address two major cardiovascular risk factors.","oneSentence":"This combination drug reduces blood pressure by blocking calcium channels in blood vessels and lowers cholesterol by inhibiting HMG-CoA reductase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:02.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension and dyslipidemia in patients requiring both agents"},{"name":"Reduction of cardiovascular risk in patients with coronary artery disease or multiple cardiovascular risk factors"}]},"trialDetails":[{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT04111419","phase":"PHASE4","title":"Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-07-01","conditions":"Atrial Fibrillation, Hypertension","enrollment":1200},{"nctId":"NCT02099123","phase":"PHASE4","title":"A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2015-07","conditions":"Independent Living, Disability Free Survival, Elderly","enrollment":9971},{"nctId":"NCT05479097","phase":"NA","title":"Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2023-02-06","conditions":"Hypertension","enrollment":32},{"nctId":"NCT05764317","phase":"","title":"Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2023-04-30","conditions":"Arterial Hypertension, HTN","enrollment":409},{"nctId":"NCT00656331","phase":"NA","title":"The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2005-08","conditions":"Hypertension","enrollment":""},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT05165251","phase":"PHASE4","title":"Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2022-01-04","conditions":"Isolated Systolic Hypertension","enrollment":480},{"nctId":"NCT05679102","phase":"NA","title":"Atorvastatin as an Antihypertensive Agent","status":"COMPLETED","sponsor":"Himayat Ullah","startDate":"2022-12-20","conditions":"Atorvastatin Antihypertensive Effect","enrollment":120},{"nctId":"NCT02850081","phase":"PHASE3","title":"Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-06-01","conditions":"Carotid Artery Stenosis, Strokes","enrollment":31},{"nctId":"NCT03951207","phase":"PHASE4","title":"Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2019-05-30","conditions":"Dyslipidemias, Hypertension","enrollment":259},{"nctId":"NCT05398393","phase":"NA","title":"An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-01-01","conditions":"Hepatitis B, Chronic, Lipid Disorder","enrollment":150},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT02913664","phase":"PHASE2, PHASE3","title":"Risk Reduction for Alzheimer's Disease","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-02-02","conditions":"Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline","enrollment":513},{"nctId":"NCT02278471","phase":"PHASE2","title":"The SCCS Polypill Pilot Trial","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Hypertension, Hyperlipidemia","enrollment":303},{"nctId":"NCT00412113","phase":"PHASE4","title":"A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-01","conditions":"Dyslipidemia, Hypertension","enrollment":245},{"nctId":"NCT01190007","phase":"PHASE4","title":"Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-08","conditions":"Hypertension, Hypercholesterolemia, Angina Pectoris","enrollment":159},{"nctId":"NCT01107743","phase":"","title":"Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-06","conditions":"Hypertension, Angina Pectoris, Hypercholesterolemia","enrollment":1291},{"nctId":"NCT00159718","phase":"PHASE4","title":"Double Blind Atorvastatin Amlodipine Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-07","conditions":"Angina","enrollment":360},{"nctId":"NCT00407537","phase":"PHASE4","title":"Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-03","conditions":"Hypertension, Hypercholesterolemia","enrollment":1531},{"nctId":"NCT00530946","phase":"PHASE3","title":"A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-09","conditions":"Hypertension, Hypercholesterolemia","enrollment":165},{"nctId":"NCT00579254","phase":"","title":"Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-12","conditions":"Hypertension and Cardiovascular Risk Factors","enrollment":112},{"nctId":"NCT00174330","phase":"PHASE4","title":"Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-05","conditions":"Hypertension, Hyperlipidemia","enrollment":330},{"nctId":"NCT00150384","phase":"PHASE4","title":"Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-07","conditions":"Hypertension, Dyslipidemia","enrollment":500},{"nctId":"NCT00174304","phase":"PHASE4","title":"Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-10","conditions":"Hypertension, Hyperlipidemia","enrollment":1120},{"nctId":"NCT00143234","phase":"PHASE3","title":"Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-05","conditions":"Hypertension, Hyperlipidemia","enrollment":1825},{"nctId":"NCT00297973","phase":"PHASE4","title":"Cardiovascular Risk Assessment in Patients Treated With Caduet","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-02","conditions":"Hypertension","enrollment":1442},{"nctId":"NCT00332761","phase":"PHASE4","title":"Caduet in an Untreated Subject Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-06","conditions":"Hypertension, Dyslipidemia","enrollment":220},{"nctId":"NCT00330785","phase":"PHASE3","title":"Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-10","conditions":"Hypertension, Dyslipidemia","enrollment":1250},{"nctId":"NCT03515772","phase":"","title":"Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2018-04-23","conditions":"HIV Infections, Drug Interactions, Cardiovascular Diseases","enrollment":21},{"nctId":"NCT04306627","phase":"PHASE4","title":"Effect of Atorvastatin on Carotid Intima Media Thickness","status":"UNKNOWN","sponsor":"Yerevan State Medical University","startDate":"2020-04-15","conditions":"Essential Hypertension, Hypercholesterolemia","enrollment":200},{"nctId":"NCT04262765","phase":"PHASE1","title":"Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin","status":"COMPLETED","sponsor":"Midas Pharma GmbH","startDate":"2019-02-23","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT04245046","phase":"PHASE1","title":"Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin","status":"COMPLETED","sponsor":"Midas Pharma GmbH","startDate":"2019-01-18","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT03047538","phase":"PHASE4","title":"Fixed Combination for Lipid and Blood Pressure Control","status":"WITHDRAWN","sponsor":"Charles University, Czech Republic","startDate":"2017-09-01","conditions":"Arterial Hypertension, Dyslipidemias, Blood Pressure","enrollment":""},{"nctId":"NCT03967496","phase":"","title":"Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors","status":"COMPLETED","sponsor":"Sultan Qaboos University","startDate":"2019-01-01","conditions":"Delirium, Anesthesia; Adverse Effect","enrollment":402},{"nctId":"NCT03860220","phase":"PHASE4","title":"The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin","status":"UNKNOWN","sponsor":"Hyo-Soo Kim","startDate":"2019-03-01","conditions":"Hypertension, Dyslipidemias","enrollment":304},{"nctId":"NCT03657472","phase":"PHASE1","title":"Bioequivalence Study of CJ-30061 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2016-09-19","conditions":"Hypertension, Hyperlipidemia","enrollment":42},{"nctId":"NCT03639480","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2017-10-13","conditions":"Hypertension, Hyperlipidemia","enrollment":180},{"nctId":"NCT03054467","phase":"PHASE4","title":"Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina","status":"UNKNOWN","sponsor":"Kosin University Gospel Hospital","startDate":"2018-12-01","conditions":"Quality of Life","enrollment":150},{"nctId":"NCT03504735","phase":"PHASE4","title":"Caduet and TLC Intervention in Metabolic Syndrome","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2005-05-01","conditions":"Metabolic Syndrome","enrollment":53},{"nctId":"NCT03461081","phase":"PHASE1","title":"Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2017-05-07","conditions":"Hypertension With Hyperlipidemia","enrollment":32},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Hypertension, Hypertension Resistant to Conventional Therapy, Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent","enrollment":4},{"nctId":"NCT02069821","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-03","conditions":"Healthy","enrollment":56},{"nctId":"NCT00805311","phase":"PHASE4","title":"Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis","status":"TERMINATED","sponsor":"Russian Cardiology Research and Production Center","startDate":"2009-04","conditions":"Carotid Artery Stenosis, Atherosclerosis, Stroke","enrollment":400},{"nctId":"NCT00081731","phase":"PHASE3","title":"Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2004-04","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular","enrollment":947},{"nctId":"NCT02295046","phase":"PHASE1","title":"Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2011-10","conditions":"Healthy","enrollment":80},{"nctId":"NCT02292069","phase":"PHASE1","title":"Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2011-09","conditions":"Healthy","enrollment":90},{"nctId":"NCT01922687","phase":"PHASE4","title":"Amlodipine Plus/Minus Atorvastatin for Protection of Arteries","status":"UNKNOWN","sponsor":"Shanghai Institute of Hypertension","startDate":"2011-04","conditions":"Arterial and Arteriolar Disorders","enrollment":109},{"nctId":"NCT01842230","phase":"PHASE1","title":"Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-04","conditions":"Essential Hypertension, Hyperlipidemia","enrollment":24},{"nctId":"NCT01842256","phase":"PHASE1","title":"Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-04","conditions":"Essential Hypertension, Hyperlipidemia","enrollment":24},{"nctId":"NCT01567774","phase":"PHASE4","title":"Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2012-04","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01665235","phase":"NA","title":"Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2012-08","conditions":"Blood Pressure Variability, Intracranial Artery Stenosis","enrollment":200},{"nctId":"NCT00741078","phase":"PHASE4","title":"Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2004-12","conditions":"Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Caduet"],"phase":"marketed","status":"active","brandName":"Amlodipine/Atorvastatin","genericName":"Amlodipine/Atorvastatin","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug reduces blood pressure by blocking calcium channels in blood vessels and lowers cholesterol by inhibiting HMG-CoA reductase. Used for Hypertension and dyslipidemia in patients requiring both agents, Reduction of cardiovascular risk in patients with coronary artery disease or multiple cardiovascular risk factors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}